Contrave is bupropion SR plus  naltrexone SR and   Empatic (formerly excalia) is bupropion SR plus zonisamide. Contrave is in  phase III trials and Excalia is in phase II trials.

During a 24 week phase II trial patients taking Contrive lost and average of 7.52% while patents taking the placebo lost 1.03% of body weight. In another trial Patients taking Excalia lost on average 9.2% of their weight from baseline using compared to an average of 0.4% taking the placebo. The Empatic trial was continued for a  further 24 week open-label period achieving an average weight loss of 12% from baseline by 48 weeks.